Sanofi Consumer Healthcare India Limited delivered impressive financial performance in Q1'26, demonstrating strong growth across multiple business segments. The company's Board of Directors approved the unaudited financial results for the quarter ended 31st March 2026 during their meeting held on 28th April 2026.

Official Regulatory Filing

The company announced its Q1'26 results through a press release filed under Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 on 30th April 2026. The announcement was made to both BSE Limited (Scrip Code: 544250) and National Stock Exchange of India Limited (Symbol: SANOFICONR).

Financial Performance Overview

The company's financial metrics for Q1'26 showed robust year-on-year growth across key parameters:

Business Segment Performance

The company's domestic operations showed strong momentum with 15.5% growth in domestic sales. This growth was primarily driven by the successful relaunch of recalled products back to the market, indicating effective operational recovery and market response.

Export sales demonstrated exceptional performance with 144% growth, though the company attributed this significant increase to a low base effect from the previous year. This substantial export growth contributed meaningfully to the overall revenue performance for the quarter.

Management Commentary

Himanshu Bakshi, Managing Director of Sanofi Consumer Healthcare India Limited, highlighted the company's disciplined execution strategy. He emphasized that the domestic business outpaced market performance, delivering both market share gains and volume growth. Bakshi noted the company's commitment to simplifying self-care and making it more accessible and effective for consumers, guided by science and driven by purpose.

Company Background

Sanofi Consumer Healthcare India Limited operates as an independent entity following its demerger from Sanofi India Limited on 1st June 2024. The company focuses exclusively on the Consumer Healthcare sector with a portfolio spanning multiple therapeutic areas:

• Allergy Care • Digestive Wellness • Pain Care • Multivitamins

The company's key brands include Allegra®, DePURA®, Avil®, and Combiflam®. With its agile business model and strong brand portfolio, the company positions itself as one of the leading players in India's consumer healthcare market, leveraging global experience to enhance customer wellbeing through accessible self-care solutions.

Sanofi Consumer Healthcare India Limited has announced its unaudited financial results for the quarter ended March 31, 2026, demonstrating strong operational performance across key metrics. The Board of Directors approved the results during a meeting held on April 28, 2026, from 1:00 p.m. to 3:40 p.m. The company has submitted the required financial documentation to both BSE Limited and National Stock Exchange of India Limited, complying with SEBI Listing Regulations.

Financial Performance Highlights

The company delivered impressive financial results for Q4FY26, with net profit reaching ₹678 million compared to ₹500 million in the corresponding quarter of the previous year, representing a 35.60% year-over-year growth. Revenue grew to ₹2,348 million from ₹1,778 million, reflecting strong business momentum of 35.29% growth.

Basic and diluted earnings per share (Rs. 10/- each) stood at ₹29.44 for Q4FY26, compared to ₹21.69 in the same quarter of the previous year. Total income from operations for the quarter ended March 31, 2026 was recorded at ₹2,348 million.

Sales Performance and Market Growth

The company reported sales of products worth ₹2,063 million for the quarter. Domestic sales demonstrated strong growth of 15.50% aided by successful product relaunches, while export sales surged by 144.40% on a lower base compared to the corresponding quarter of the previous year.

Product Portfolio Impact

The company had voluntarily recalled Depura Kids, Allegra Suspension and Combiflam Suspension in 2024 as a precautionary measure. Combiflam Suspension was successfully relaunched during the quarter ended June 2025, while Allegra Suspension and Depura Kids were relaunched in the quarter ended September 2025. These strategic relaunches contributed to the improved domestic sales performance.

Regulatory Compliance Updates

The company addressed the impact of New Labour Codes notified by the Government of India effective November 21, 2025. An incremental financial impact of ₹24 million was recognized as past service cost, resulting in increased gratuity liability and compensated absences due to changes in wage definitions under Employee Benefits Expense. The company does not have any subsidiary, associate or joint ventures as on March 31, 2026.

Newspaper Publication Compliance

Following regulatory requirements, the company published its Q4FY26 unaudited financial results in newspapers on April 29, 2026. The publication appeared in Business Standard and Sakal newspapers, fulfilling the mandatory disclosure obligations under SEBI regulations. The company formally intimated both BSE Limited and National Stock Exchange of India Limited about the newspaper publication through official correspondence dated April 30, 2026.